ANIP Quote, Financials, Valuation and Earnings

Amphastar Pharmaceuticals has a net margin of -5.39% compared to ANI Pharmaceuticals's net margin of 20.35%. ANI Pharmaceuticals's return on equity of -4.07% beat Amphastar Pharmaceuticals's return on equity of 22.89%.

ANI Pharmaceuticals has a consensus price target of $81.50, signalling upside risk potential of 25.64%. On the other hand Amphastar Pharmaceuticals has an analysts' consensus of $39.00 which suggests that it could grow by 39.99%. Given that Amphastar Pharmaceuticals has higher upside potential than ANI Pharmaceuticals, analysts believe Amphastar Pharmaceuticals is more attractive than ANI Pharmaceuticals.

ANI Pharmaceuticals has a beta of 0.625, which suggesting that the stock is 37.453% less volatile than S&P 500. In comparison Amphastar Pharmaceuticals has a beta of 0.768, suggesting its less volatile than the S&P 500 by 23.238%.

ANI Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amphastar Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ANI Pharmaceuticals pays -8.77% of its earnings as a dividend. Amphastar Pharmaceuticals pays out -- of its earnings as a dividend.

ANI Pharmaceuticals quarterly revenues are $190.6M, which are larger than Amphastar Pharmaceuticals quarterly revenues of $186.5M. ANI Pharmaceuticals's net income of -$10.3M is lower than Amphastar Pharmaceuticals's net income of $38M. Notably, ANI Pharmaceuticals's price-to-earnings ratio is 55.43x while Amphastar Pharmaceuticals's PE ratio is 9.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ANI Pharmaceuticals is 2.05x versus 1.98x for Amphastar Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Inovio Pharmaceuticals has a net margin of -5.39% compared to ANI Pharmaceuticals's net margin of -16566.39%. ANI Pharmaceuticals's return on equity of -4.07% beat Inovio Pharmaceuticals's return on equity of -119.02%.

ANI Pharmaceuticals has a consensus price target of $81.50, signalling upside risk potential of 25.64%. On the other hand Inovio Pharmaceuticals has an analysts' consensus of $7.83 which suggests that it could grow by 299.66%. Given that Inovio Pharmaceuticals has higher upside potential than ANI Pharmaceuticals, analysts believe Inovio Pharmaceuticals is more attractive than ANI Pharmaceuticals.

ANI Pharmaceuticals has a beta of 0.625, which suggesting that the stock is 37.453% less volatile than S&P 500. In comparison Inovio Pharmaceuticals has a beta of 0.917, suggesting its less volatile than the S&P 500 by 8.256%.

ANI Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Inovio Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ANI Pharmaceuticals pays -8.77% of its earnings as a dividend. Inovio Pharmaceuticals pays out -- of its earnings as a dividend.

ANI Pharmaceuticals quarterly revenues are $190.6M, which are larger than Inovio Pharmaceuticals quarterly revenues of $117K. ANI Pharmaceuticals's net income of -$10.3M is higher than Inovio Pharmaceuticals's net income of -$19.4M. Notably, ANI Pharmaceuticals's price-to-earnings ratio is 55.43x while Inovio Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ANI Pharmaceuticals is 2.05x versus -- for Inovio Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Viemed Healthcare has a net margin of -5.39% compared to ANI Pharmaceuticals's net margin of 7.11%. ANI Pharmaceuticals's return on equity of -4.07% beat Viemed Healthcare's return on equity of 9.21%.

ANI Pharmaceuticals has a consensus price target of $81.50, signalling upside risk potential of 25.64%. On the other hand Viemed Healthcare has an analysts' consensus of $12.83 which suggests that it could grow by 69.31%. Given that Viemed Healthcare has higher upside potential than ANI Pharmaceuticals, analysts believe Viemed Healthcare is more attractive than ANI Pharmaceuticals.

ANI Pharmaceuticals has a beta of 0.625, which suggesting that the stock is 37.453% less volatile than S&P 500. In comparison Viemed Healthcare has a beta of 1.504, suggesting its more volatile than the S&P 500 by 50.437%.

ANI Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viemed Healthcare offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ANI Pharmaceuticals pays -8.77% of its earnings as a dividend. Viemed Healthcare pays out -- of its earnings as a dividend.

ANI Pharmaceuticals quarterly revenues are $190.6M, which are larger than Viemed Healthcare quarterly revenues of $60.7M. ANI Pharmaceuticals's net income of -$10.3M is lower than Viemed Healthcare's net income of $4.3M. Notably, ANI Pharmaceuticals's price-to-earnings ratio is 55.43x while Viemed Healthcare's PE ratio is 27.07x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ANI Pharmaceuticals is 2.05x versus 1.38x for Viemed Healthcare. Usually stocks with elevated PS ratios are considered overvalued.

Viatris has a net margin of -5.39% compared to ANI Pharmaceuticals's net margin of -14.64%. ANI Pharmaceuticals's return on equity of -4.07% beat Viatris's return on equity of -3.22%.

ANI Pharmaceuticals has a consensus price target of $81.50, signalling upside risk potential of 25.64%. On the other hand Viatris has an analysts' consensus of $11.7625 which suggests that it could grow by 24.87%. Given that ANI Pharmaceuticals has higher upside potential than Viatris, analysts believe ANI Pharmaceuticals is more attractive than Viatris.

ANI Pharmaceuticals has a beta of 0.625, which suggesting that the stock is 37.453% less volatile than S&P 500. In comparison Viatris has a beta of 0.922, suggesting its less volatile than the S&P 500 by 7.819%.

ANI Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viatris offers a yield of 5.1% to investors and pays a quarterly dividend of $0.12 per share. ANI Pharmaceuticals pays -8.77% of its earnings as a dividend. Viatris pays out -90.63% of its earnings as a dividend.

ANI Pharmaceuticals quarterly revenues are $190.6M, which are smaller than Viatris quarterly revenues of $3.5B. ANI Pharmaceuticals's net income of -$10.3M is higher than Viatris's net income of -$516.5M. Notably, ANI Pharmaceuticals's price-to-earnings ratio is 55.43x while Viatris's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ANI Pharmaceuticals is 2.05x versus 0.77x for Viatris. Usually stocks with elevated PS ratios are considered overvalued.